KR20230086674A - 파킨슨 질환의 치료 - Google Patents

파킨슨 질환의 치료 Download PDF

Info

Publication number
KR20230086674A
KR20230086674A KR1020237011924A KR20237011924A KR20230086674A KR 20230086674 A KR20230086674 A KR 20230086674A KR 1020237011924 A KR1020237011924 A KR 1020237011924A KR 20237011924 A KR20237011924 A KR 20237011924A KR 20230086674 A KR20230086674 A KR 20230086674A
Authority
KR
South Korea
Prior art keywords
subject
pracinezumab
disease
parkinson
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237011924A
Other languages
English (en)
Korean (ko)
Inventor
겐나로 파가노
와그너 자고
Original Assignee
프로테나 바이오사이언시즈 리미티드
에프. 호프만-라 로체 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로테나 바이오사이언시즈 리미티드, 에프. 호프만-라 로체 에이지 filed Critical 프로테나 바이오사이언시즈 리미티드
Publication of KR20230086674A publication Critical patent/KR20230086674A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237011924A 2020-09-10 2021-09-10 파킨슨 질환의 치료 Pending KR20230086674A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063076916P 2020-09-10 2020-09-10
US202063076915P 2020-09-10 2020-09-10
US202063076913P 2020-09-10 2020-09-10
US63/076,915 2020-09-10
US63/076,916 2020-09-10
US63/076,913 2020-09-10
US202163158191P 2021-03-08 2021-03-08
US63/158,191 2021-03-08
PCT/US2021/049785 WO2022056209A1 (en) 2020-09-10 2021-09-10 Treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
KR20230086674A true KR20230086674A (ko) 2023-06-15

Family

ID=80629905

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237011924A Pending KR20230086674A (ko) 2020-09-10 2021-09-10 파킨슨 질환의 치료

Country Status (10)

Country Link
US (2) US12084491B2 (enExample)
EP (1) EP4211162A4 (enExample)
JP (1) JP2023541048A (enExample)
KR (1) KR20230086674A (enExample)
AU (1) AU2021338781A1 (enExample)
CR (1) CR20230121A (enExample)
IL (1) IL301039A (enExample)
MX (1) MX2023002851A (enExample)
TW (1) TW202227131A (enExample)
WO (1) WO2022056209A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
US20240279316A1 (en) * 2022-12-29 2024-08-22 Astrazeneca Ab Compositions and methods for treating alpha-synucleinopathies
IL326387A (en) * 2023-09-14 2026-04-01 Hoffmann La Roche Antibody formulation
CN117409969B (zh) * 2023-11-13 2026-04-03 深圳市臻络科技有限公司 帕金森病运动功能评估方法、装置及电子设备

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7981058B2 (en) 2004-03-12 2011-07-19 The Trustees Of Dartmouth College Intelligent wearable monitor systems and methods
US20060122472A1 (en) 2004-09-28 2006-06-08 Pullman Seth L System and method for clinically assessing motor function
US8702629B2 (en) 2005-03-17 2014-04-22 Great Lakes Neuro Technologies Inc. Movement disorder recovery system and method for continuous monitoring
US20070092889A1 (en) 2005-06-02 2007-04-26 Perlegen Sciences, Inc. Parkinson's disease-related disease compositions and methods
JP5251270B2 (ja) 2008-06-04 2013-07-31 三菱化学株式会社 パーキンソン病の評価装置
RU2540470C9 (ru) * 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона
US20100076348A1 (en) 2008-09-23 2010-03-25 Apdm, Inc Complete integrated system for continuous monitoring and analysis of movement disorders
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
CN101963919A (zh) 2009-07-24 2011-02-02 鸿富锦精密工业（深圳）有限公司 进程管理系统
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9924899B2 (en) 2013-09-09 2018-03-27 Alexis Pracar Intelligent progression monitoring, tracking, and management of parkinson's disease
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
JP6595490B2 (ja) 2014-02-04 2019-10-23 ザ メディカル リサーチ， インフラストラクチャー， アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター 身体固定センサを使用してパーキンソン病の診断または予後を提供する方法およびシステム
US20180126158A1 (en) 2016-08-22 2018-05-10 Lyriq, Llc Systems and Methods for Functional Restoration and Rehabilitation of Posture, Gait and Movement
JOP20190227A1 (ar) 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
CA3076313A1 (en) * 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
EP3833435B1 (en) 2018-08-09 2025-09-24 F. Hoffmann-La Roche AG Determination of parkinson's disease
KR20230154249A (ko) 2021-03-08 2023-11-07 프로테나 바이오사이언시즈 리미티드 파킨슨 질환의 치료

Also Published As

Publication number Publication date
US12084491B2 (en) 2024-09-10
US20220098291A1 (en) 2022-03-31
WO2022056209A1 (en) 2022-03-17
TW202227131A (zh) 2022-07-16
US20250188158A1 (en) 2025-06-12
MX2023002851A (es) 2023-03-22
CR20230121A (es) 2023-07-26
EP4211162A4 (en) 2025-04-30
EP4211162A1 (en) 2023-07-19
JP2023541048A (ja) 2023-09-27
AU2021338781A1 (en) 2023-03-30
IL301039A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
Quinn et al. Amyotrophic lateral sclerosis and other motor neuron diseases
US12084491B2 (en) Treatment of Parkinson's disease
JP2020055881A (ja) 脱髄障害の治療のための併用療法および使用
US20110053859A1 (en) Methods to reduce the effects of sleep deprivation
US20210277111A1 (en) Lingo-1 antagonists and uses for treatment of demyelinating disorders
JP7642735B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
WO2016167263A1 (ja) Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
CN119095617A (zh) 用于治疗患有头皮斑块型银屑病的受试者的方法
CN118055767A (zh) 新颖的组合施用
RU2848183C1 (ru) Лечение болезни паркинсона
US20240043545A1 (en) Methods and compositions for treatment of thyroid eye disease
JP2023532882A (ja) レット症候群の処置のためのセマフォリン４ｄ結合分子の使用
CN116802208A (zh) 帕金森氏病的治疗
RU2786476C2 (ru) Композиция, содержащая антитело против протофибрилл абета и ингибитор бета-секретазы васе1 для лечения болезни альцгеймера
Neroeva et al. Features of local expression of genes of immune response cytokines and trophic and vasoregulatory factors in modeling of retinal pigment epithelium atrophy
JP2023529347A (ja) 鼻茸を伴う患者における重度の喘息を処置する方法
Kaplan et al. Measurement of enterovirus-specific IgG in intravenous immunoglobulin preparations
Sullivan et al. New treatment strategy for systemic mastocytosis
KR20250148576A (ko) 알파-시누클레인병증을 치료하기 위한 조성물 및 방법
Class et al. Patent application title: METHODS TO REDUCE THE EFFECTS OF SLEEP DEPRIVATION Inventors: Samuel A. Deadwyler (Lewisville, NC, US) Robert E. Hampson (Kernersville, NC, US) Linda Porrino (Lewisville, NC, US) Michael Todd (Winston Salem, NC, US) Thomas N. Thannickal (Winnetka, CA, US) Yuan-Yan Lai (North Hills, CA, US) Jerome M. Siegel (Northridge, CA, US) Assignees: The US Government Respresented by the Department of Veterans Affairs
Welch Uncertainties and concerns in viewing migraine as a progressive disorder; an analysis of clinical and imaging studies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230406

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240902

Comment text: Request for Examination of Application